Intra Cellular Therapies reported $782M in Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
Acadia Pharmaceuticals ACAD:US USD 602.49M 10.28M
ALKERMES ALKS:US USD 1.94B 15.52M
Aptinyx Inc APTX:US USD 76.2M 16.1M
Biocryst Pharmaceuticals BCRX:US USD 558.59M 48.06M
Biogen BIIB:US USD 24.85B 227.2M
Cytokinetics CYTK:US USD 1.08B 304.24M
Esperion Therapeutics ESPR:US USD 312.83M 8.85M
Gilead Sciences GILD:US USD 63.17B 614M
Halozyme Therapeutics HALO:US USD 1.86B 83.15M
Intra Cellular Therapies ITCI:US USD 782M 29.91M
JAZZ PHA JAZZ:US USD 10.38B 815.47M
Marinus Pharmaceuticals MRNS:US USD 184.84M 75.46M
Minerva Neurosciences NERV:US USD 59.76M 5.2M
Nektar Therapeutics NKTR:US USD 781.01M 80.98M
Novartis NVS:US USD 117.45B 1.01B
Prothena PRTA:US USD 554.44M 4.85M
Supernus Pharmaceuticals SUPN:US USD 1.69B 1.84M
United Therapeutics UTHR:US USD 5.78B 238.3M
Vanda Pharmaceuticals VNDA:US USD 621.79M 12.69M